Zota Health Care Ltd. · NSE:ZOTA
Zota Health Care — Q2 FY2023 Earnings Presentation
28 slides from Zota Health Care's earnings presentation, Nov 22, 2022
Slide 1: Cover letter to NSE for Investor Presentation
November 22, 2022 To, The Manager Listing Department, The National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai – 400051 Dear Sir/Madam, Trading Symbol: ZOTA Sub: Investor Presentation Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirem
Slide 2: Q2FY23 Performance Highlights
NOVEMBER 2022 Q2FY23 PERFORMANCE HIGHLIGHTS
Slide 3: Safe Harbour
Safe Harbour 02 zotahealthcare.com This presentation has been prepared by the Zota Health Care Limited (the “Company”) only for information purpose to the stakeholders and does not contain any offer or invitation to subscribe the securities of the Company. No offering of securities shall be made exc
Slide 4: Table of Contents
Table of Contents 04 RESULT HIGHLIGHTS 07 OPERATIONAL METRICS 11 DAVAINDIA 20 BUSINESS OUTLOOK & STRATEGY 24 FINANCIAL SUMMARY
Slide 5: Q2FY23 Result Highlights
1 05 06 Q2FY23 Result Highlights Stand Quarterly Financial Highlights Revenue Break up – Quarterly zotahealthcare.com
Slide 6: Standalone Quarterly Financial Highlights
Stand Quarterly Financial Highlights 5 zotahealthcare.com Q-o-Q Y-o-Y Revenues (₹ Lakhs) Gross Profit (%) Revenues (₹ Lakhs) Gross Profit (%) 37.30% 37.12% 3,857.26 37.12% 3,857.26 3,539.70 33.82% 2,948.78 Q1-FY23 Q2-FY23 Q1-FY23 Q2-FY23 Q1-FY23 Q2-FY23 Q1-FY23 Q2-FY23 Operating Profit (₹ Lakhs) PAT
Slide 7: Revenue Break up - Quarterly
Revenue Break up- Quar terly 06 zotahealthcare.com Domestic Sales Q2-FY23 Q1-FY23 Q2-FY22 Dava India Sales 3,857 2,949 3,540 Export Sales (SEZ)
Slide 8: Highlights: P&L Statement and Management Commentary
2 08 09 FY Result Highlights Stand Profit & Loss Statement – Quarterly Management Commentary zotahealthcare.com
Slide 9: Standalone Profit & Loss Statement - Quarterly
Stand Profit & Loss Statement- Quar terly 08 zotahealthcare.com Particulars (Rs Lakhs) Q2FY23 Q1FY23 YoY % QoQ % Q2FY22 Export Sales (SEZ) 903.9 766.6 -9% 18% 991.7 Dava India Sales 1217.1 1019.3 44% 19% 848.1 Domestic Sales 1736.3 1162.8 2% 49% 1,699.9 Revenues from Operations 3,857.26 2,948.78 9%
Slide 10: Management Commentary
Management Commentar y 09 zotahealthcare.com 1 3 5 The Company reported a Domestic Sales reported an The sales contribution from comeback in Revenues in increase of 49% YoY and 2% new-age business stood at Q2FY22, on account of higher QoQ, at the same time Export 51% in Q2FY23 as compare throughput
Slide 11: Management Commentary: Domestic Operations and Exports
Management Commentar y 10 zotahealthcare.com 1 DOMESTIC OPERATIONS 2 EXPORTS Domestic Revenues increased by 35.34% Exports revenues increased by QoQ and a growth of 15.91% YoY at ₹ 17.91% on QoQ basis and declined 2953.39 Lakhs in Q2FY23 supported by by 8.85% YoY at ₹ 903.9 Lakhs in healthy performa
Slide 12: Davaindia Generic Pharmacy
3 12 14 Generic Phar macy Davaindia Davaindia Key Figures Davaindia- Generic Pharmacy 16 Davaindia- COCO Stores 17 Operational FOFO Stores 18 Operational COCO Stores 19 Management Commentary zotahealthcare.com
Slide 13: Davaindia Key Figures
Davaindia Key Figures 12 zotahealthcare.com Gross Mercantile Value (GMV) Total GMV of Davaindia Stores stood at 1,926 Lakhs during Q2FY23 an increase of 21% QoQ No. of SKU’s New Stores rolled-out 1,692 59 51 1,653 1,644 34 31 1,614 Q3-FY22 Q4-FY22 Q1-FY23 Q2-FY23 Q3-FY22 Q4-FY22 Q1-FY23 Q2-FY23
Slide 14: Davaindia Key Figures: Customers Served and Wallet Spend
13 zotahealthcare.com 7,59,207 Q1-FY23 6,43,120 Q1-FY23 6,41,712 Q4-FY22 5,68,183 Q3-FY22 Davaindia Key Figures 5,40,924 Q2-FY22 No. of Customers Served 4,73,181 Q1-FY22 4,40,458 Q4-FY21 3,23,395 Q3-FY21 3,52,623 Q2-FY21 254 Q2-FY23 248 Q1-FY23 267 Q4-FY22 237 Q3-FY22 229 Q2-FY22 Average Wallet Spen
Slide 15: Davaindia - Generic Pharmacy
Davaindia- Generic Phar macy 14 zotahealthcare.com During the quarter Davaindia has Davaindia has led the revolution Davaindia retail pharmacy stores’ catered to the highest-ever number of of patients opting for generic focus continues to be chronic customer i.e. 7.59 lakhs against 6.43 medicines ag
Slide 16: Davaindia - Generic Pharmacy
Davaindia- Generic Phar macy 15 zotahealthcare.com
Slide 17: Davaindia - COCO Stores
Davaindia- COCO Stores 16 zotahealthcare.com
Slide 18: Operational FOFO Stores
Operational 17 zotahealthcare.com FOFO States Uttar Pradesh No. of Stores 104 Stores Madhya Pradesh Gujarat 70 55 Maharashtra 52 Odisha 52 Delhi 32 Haryana 31 West Bengal 30 Rajasthan 28 Kerala 19 Bihar 17 Tamil Nadu 11 Karnataka 10 Assam 8 562 Jharkhand 7 Telangana 7 Operational FOFO stores Punjab
Slide 19: Operational COCO Stores
Operational 18 zotahealthcare.com COCO States Gujarat No. of Stores 14 Stores Maharashtra Rajasthan 13 5 Uttar Pradesh 4 Delhi 3 Haryana 2 Madhya Pradesh 1 42 Operational COCO stores as on 30.09.2022 Company Owned Company Operated (COCO) Stores Operated by wholly-owned subsidiary Davaindia Health Ma
Slide 20: Management Commentary
Management Commentar y 19 zotahealthcare.com Commenting on Q2FY23 financial performance and operational highlights, Management Team of Zota Health Care said, “The Company has made a comeback in Q2FY23 after a challenging Q1. With stabilization of operations post shifting to the new warehousing facil
Slide 21: Industry Snapshot
4 21 22 Industr y Snapshot Retail Generic Medicine Landscape in India Impact of PMBJP 23 Underpenetrated Generic Medicine Market zotahealthcare.com
Slide 22: Retail Generic Medicine Landscape in India
Retail Generic Medicine Landscape in India 21 zotahealthcare.com To achieve the objective of Objectives Savings to the Strong making available quality generic of PMBJP common man Implementation medicines at affordable prices to • To make available quality • A medicine under • The Product Basket of m
Slide 23: Impact of PMBJP
Impact of PMBJP 22 zotahealthcare.com In the financial year (2019-20), PMBJP has achieved sales of ₹258 crores (at MRP), up to 30-11-2019. This has led to savings of approximately ₹1,800 crores of the common citizens of the country. Growth in number of stores* Growth in turnover* Product basket* Pri
Slide 24: Underpenetrated Generic Medicine Market
Underpenetrated Generic Medicine Market 23 zotahealthcare.com 4 pillars to drive healthcare Branded and generic mix of Indian pharma market (%) 4 As of healthcare Generic GX Branded GX Overall India 8 Accessibility Affordability Awarness Aliments • Setting up of • Higher per • Rising literacy • Grow
Slide 25: Financial Summary
5 25 26 Financial Summary Profit & Loss Statement Balance Sheet & Key Ratios zotahealthcare.com
Slide 26: Profit & Loss Statement
Profit & Loss Statement 25 zotahealthcare.com Particulars (INR Lakhs) FY15 FY16 FY17 FY18 FY19 FY20 FY21 FY22 Income from Operations 5,646.3 6,473.3 7,158.0 7,785.2 8,562.9 9,511.3 10,684.12 13,153.33 Other Income 1.4 7.7 5.6 151.9 154.5 151.3 125.66 164.56 Total Income 5,647.8 6,481.0 7,163.6 7,937
Slide 27: Balance Sheet & Key Ratios
Balance Sheet & Key Ratios 26 zotahealthcare.com Particulars (INR Lakhs) FY14 FY15 FY16 FY17 FY18 FY19 FY20 FY21 FY22 Share capital 1,196.9 1,436.3 1,436.3 1,436.3 1,754.3 1,754.3 2,456.0 2456.03 2,516.0 Reserves and Surplus 384.2 395.7 707.8 1,262.0 5,223.4 5,138.2 4,426.9 4,181.2 6,621.4 Non-curre
Slide 28: Thank You
Thank You Contact Infor mation M r. Himanshu Zota / M r. Ashvin Variya "ZOTA HOUSE", 2/896, Hira Modi Street, Sagrampura, Surat-395 002(Gujarat) cszota@zotahealthcare.com www.zotahealthcare.com